SCHEMBL1640547

SCHEMBL1640547

NC(=S)NCCCN1CCOCC1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.74
DUSP3 P51452 1/20 0.74
GAA P10253 4/20 0.66
LMNA P02545 3/20 0.59
KDM4E B2RXH2 1/20 0.59
CA12 O43570 1/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
CA9 Q16790 1/20 0.53
ALDH1A1 P00352 3/20 0.53
MAPK1 P28482 2/20 0.53
HIF1A Q16665 1/20 0.53
RECQL P46063 1/20 0.52
RAB9A P51151 1/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
MAPT P10636 1/20 0.50
PKM P14618 1/20 0.50
KEAP1 Q14145 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2830503 0.93 HPGD (0.65) HPGDDUSP3GAALMNAKDM4E
SCHEMBL1606290 0.89 CA12 (0.66) HPGDDUSP3GAALMNAKDM4E
SCHEMBL4512998 0.83 HPGD (0.50) HPGDDUSP3GAAKDM4ECA12
SCHEMBL3229195 0.83 HPGD (0.81) HPGDDUSP3GAALMNAKDM4E
SCHEMBL5429820 0.83 HPGD (0.60) HPGDDUSP3GAALMNAKDM4E
SCHEMBL16450869 0.82 HPGD (0.74) HPGDDUSP3GAALMNAKDM4E
SCHEMBL6206098 0.82 GAA (0.66) HPGDDUSP3GAALMNAKDM4E
SCHEMBL3903156 0.82 GAA (0.76) HPGDDUSP3GAALMNAKDM4E
SCHEMBL29526410 0.81 CA12 (0.50) HPGDDUSP3GAAKDM4ECA12
SCHEMBL14468582 0.79 HPGD (0.70) HPGDDUSP3GAALMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117510413-A DCLK1 kinase inhibitor and preparation method and application thereof 杭州医学院 2024-02-06 CN claimed
CN-107189197-B Comprehensive conveying pipe for high-strength insulating flame-retardant pipeline gallery 上海中塑管业有限公司 2020-05-12 CN claimed
CN-105385011-B A kind of TPV compositions and automobile collision preventing billot 嘉兴市博尔塑胶有限公司 2018-07-31 CN claimed
CN-106220994-B A kind of high intensity PP-RCT anti-flaming tubular products and preparation method 刘志光 2018-06-01 CN claimed
EP-2040711-A2 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS Amphora Discovery Corporation (US) 2009-04-01 EP claimed
WO-2007136592-A2 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS AMPHORA DISCOVERY CORPORATION (US) 2007-11-29 WO claimed
CN-114450283-B 3, 6-Diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their use as pro-apoptotic agents 法国施维雅药厂 2024-05-07 CN disclosed
CN-117510413-A DCLK1 kinase inhibitor and preparation method and application thereof 杭州医学院 2024-02-06 CN disclosed
EP-4003988-A1 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS Les Laboratoires Servier (FR) 2022-06-01 EP disclosed
CN-114450283-A 3, 6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their use as pro-apoptotic agents 法国施维雅药厂 2022-05-06 CN disclosed
CN-107189197-B Comprehensive conveying pipe for high-strength insulating flame-retardant pipeline gallery 上海中塑管业有限公司 2020-05-12 CN disclosed
CN-105385011-B A kind of TPV compositions and automobile collision preventing billot 嘉兴市博尔塑胶有限公司 2018-07-31 CN disclosed
CN-106220994-B A kind of high intensity PP-RCT anti-flaming tubular products and preparation method 刘志光 2018-06-01 CN disclosed
US-20020188015-A1 Method and composition for rejuvinating cells, tissues organs, hair and nails FARRINGTON PHARMACEUTICALS, LLC 2002-12-12 US disclosed
WO-2002083863-A2 THIAZOLE AND OTHER HETEROCYCLIC LIGANDS AND USE THEREOF SEPRACOR, INC. (US) 2002-10-24 WO disclosed
WO-2002062301-A2 METHOD AND COMPOSITION FOR REJUVINATING CELLS, TISSUES, ORGANS, HAIR AND NAILS FARRINGTON PHARMACEUTICALS, LLC (US) 2002-08-15 WO disclosed
EP-0790997-A2 6-ARYL PYRIDO( 2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION WARNER-LAMBERT COMPANY (US) 1997-08-27 EP disclosed
EP-0230334-B1 A INDENOTHIAZOLE DERIVATIVE AND PROCESS FOR PREPARING THE SAME HISAMITSU PHARMACEUTICAL CO., INC. (JP) 1992-05-06 EP disclosed
US-4877876-A ANTIULCER AGENTS HISAMITSU PHARMACEUTICAL CO., INC. (JP) 1989-10-31 US disclosed
EP-0230334-A1 A indenothiazole derivative and process for preparing the same HISAMITSU PHARMACEUTICAL CO., INC. (JP) 1987-07-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020188015-A1 Method and composition for rejuvinating cells, tissues organs, hair and nails TERT, TELO2, HKDC1 HPGD 3684/4885DUSP3 1624/4885GAA 3996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.